CAMBRIDGE, Mass., Sept. 07, 2017 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company
focused on the development of potentially curative therapeutics using CRISPR/Cas9 technology, will present at key September
investor healthcare conferences. The Company also has appointed Lindsey Trickett as Vice President of Investor Relations.
Upcoming Conferences:
Tuesday, September 12, 2017
Rodman & Renshaw 19th Annual Global Investment Conference
Who: Nessan Bermingham, Ph.D., President, Chief Executive Officer and Founder
Location: New York, New York
Presentation Time: 2:35 pm EDT
Tuesday, September 26, 2017
Cantor Fitzgerald 3rd Annual Healthcare Conference
Who: Tom Barnes, Ph.D., Senior Vice President, Innovative Sciences & eXtellia
Location: New York, New York
Presentation Time: 9:10 am EDT
Wednesday, September 27, 2017
Leerink Partners Roundtable Series: Rare Disease & Immuno-Oncology
Who: Nessan Bermingham, Ph.D., President, Chief Executive Officer and Founder
Location: New York, New York
Presentation Time: 11:00 am EDT
A live webcast of Intellia’s presentations will be accessible through the Events and Presentations page of the Investor
Relations section of the company’s website at www.intelliatx.com. To access the webcasts, please log on to the Intellia website approximately
15 minutes prior to the start time to ensure adequate time for any software downloads that may be required. A replay of the webcast
will be available on Intellia’s website for 14 days following each conference.
Lindsey Trickett joins Intellia as Vice President, Investor Relations, and will be responsible for leading and overseeing all
aspects of Investor Relations activities. Lindsey brings to Intellia more than 12 years of biopharmaceutical experience in varying
roles of increasing responsibility at AstraZeneca and Medimmune, including Treasury, Capital Management and Operations Strategy.
Most recently Lindsey was a Director of Investor Relations at AstraZeneca for the North American investor base focusing on
immuno-oncology and cardiovascular and metabolic diseases. Lindsey earned a degree in International Economics at the University of
Kentucky in Lexington and her Masters of Business Administration with a focus in Finance from Georgetown University in Washington,
D.C.
About Intellia Therapeutics
Intellia Therapeutics is a leading genome editing company focused on the development of proprietary, potentially curative
therapeutics using the CRISPR/Cas9 system. Intellia believes the CRISPR/Cas9 technology has the potential to transform medicine by
permanently editing disease-associated genes in the human body with a single treatment course. Our combination of deep scientific,
technical and clinical development experience, along with our leading intellectual property portfolio, puts us in a unique position
to unlock broad therapeutic applications of the CRISPR/Cas9 technology and create a new class of therapeutic products. Learn more
about Intellia Therapeutics and CRISPR/Cas9 at intelliatx.com; Follow us on Twitter @intelliatweets.
Intellia Contacts: Media Contact: Jennifer Mound Smoter Senior Vice President, External Affairs & Communications +1 857-706-1071 jenn.smoter@intelliatx.com Investor Contact: Lindsey Trickett Vice President, Investor Relations +1 857-285-6211 lindsey.trickett@intelliatx.com
